Health Care · Biological Products, (No Diagnostic Substances)

CHRS Coherus Oncology, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1512762100 filings
Russell 2000

CHRS at a glance

Coherus Oncology, Inc. (CHRS, SEC CIK 1512762) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Coherus Oncology, Inc. (CHRS) shares worth $32.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$42.2M
−84.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$32.7M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $14.3M, up $2.7M YoY from $11.6M, driven by LOQTORZI volume growth
  • LOQTORZI best-performing product: revenue $14.0M vs $11.2M YoY
  • Gross margin figures not disclosed; operating profitability pressured by $3.4M debt extinguishment loss
  • Cash and investments $83.6M vs $172.1M at December 31, 2025; operating cash use $154.0M
  • 2026 revenue expected higher, but substantial doubt remains about continuing as a going concern within one year

Risk Factors

  • Newly emphasized going-concern risk: $83.6 million liquidity and $1.5 billion accumulated deficit after UDENYCA divestiture
  • Commercial risk: LOQTORZI faces penpulimab competition following its April 2025 FDA approval for nasopharyngeal carcinoma
  • Regulatory risk: OBBBA Medicaid funding reductions could reduce LOQTORZI sales through lower enrollment and coverage
  • Operational risk: U.S. onshoring of LOQTORZI, casdozokitug and tagmokitug manufacturing may face approval delays
  • Financial risk: UDENYCA earnouts are uncertain, with $37.5 million payments tied to $300 million and $350 million sales thresholds

AI summary of the CHRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $14.3M, up from $11.6M, while LOQTORZI revenue reached $14.0M, up 25% year over year
  • Strategic reset prioritizes tagmokitug/toripalimab in esophageal cancer, while deprioritizing other indications
Filed Oct 29, 2026Full analysis →

Item 8.01: Other Events

  • Tagmokitug showed strongest signal in first-line ESCC: post-cutoff cORR 89% (8/9), including 100% in PD-L1-positive patients
  • Second-line ESCC 700 mg arm: 16.7% cORR, 33.3% CBR and 5.5-month mPFS versus ~3.4-month chemotherapy benchmark

Item EX-99.1: Item EX-99.1

  • Tagmokitug first-line ESCC data strengthened development case: cORR 75% across PD-L1 status and 100% in PD-L1-positive patients
  • Post-cutoff cORR increased to 89% (8/9), but based on a very small, early-stage efficacy dataset

Item 7.01: Regulation FD Disclosure

  • Interim clinical data announced from TREGCHECK™ program evaluating tagmokitug in combination with toripalimab
  • Study includes regimens with or without chemotherapy
Filed Aug 28, 2026Full analysis →

Item 8.01: Other Events

  • At-the-market equity facility enabling up to $50.0 million in common-stock sales
  • No obligation to issue shares, preserving financing flexibility but creating potential dilution

AI summaries of CHRS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CHRS

Don't miss the next CHRS filing

  • Alerts as it files. A push when CHRS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CHRS, by share count.
  • Ask anything. An AI agent that reads every CHRS filing and answers with sources.

CHRS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Newcomer Lee NisleyAJun 5, 2026-
Karachun Rita AAJun 5, 2026-
Wahlstrom MatsAJun 5, 2026-
Wahlstrom MatsAJun 5, 2026-
Ryan Michael LeeAJun 5, 2026-
O'Donnell-Tormey JillAJun 5, 2026-
Newton Charles W.AJun 5, 2026-
O'Donnell-Tormey JillAJun 5, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$267.0M$42.2M
Operating Income-$203.2M-$111.7M-$181.1M
Net Income-$237.9M$28.5M$168.0M
Op. Margin--41.8%-429.5%
Net Margin-10.7%398.4%
Balance Sheet
Total Assets$629.6M$448.5M$258.3M
Equity-$193.4M-$132.0M$61.0M
ROE123.0%-21.6%275.4%
Per Share
EPS$-2.53$0.25$1.43
Cash Flow
Operating CF--$20.4M-$138.5M
CapEx$286K--

Source: XBRL data in Coherus Oncology, Inc. (CHRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CHRS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CHRS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$32.7M
Q2 202622$40.3M
Q1 202622$44.2M
Q4 202520$39.4M
Q3 202519$44.8M
Q2 202520$21.7M
Q1 202518$16.4M
Q4 202414$24.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 157 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CHRS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
8-KOct 29, 2026Analysis-
8-KAug 28, 2026Analysis-
8-KAug 17, 2026Analysis-
8-KAug 17, 2026Analysis-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
SC 13GJul 27, 2026-
8-KJun 15, 2026Analysis-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
8-KJun 1, 2026Analysis
10-QMay 11, 2026Analysis
8-KMay 11, 2026Analysis
10-KMar 9, 2026-
8-KMar 9, 2026Analysis-
8-KFeb 17, 2026-
SC 13GFeb 5, 2026-
8-KFeb 4, 2026-

Related Health Care companies

All Health Care →

CHRS SEC filings: frequently asked questions

Which institutions hold CHRS stock?

As of September 30, 2026, the largest Coherus Oncology, Inc. (CHRS) holders among the 13F filers tracked by SignalX were BlackRock ($14.2 million), Vanguard Capital Management LLC ($6.8 million), State Street Corp ($2.9 million), Goldman Sachs Group ($2.4 million), Northern Trust ($1.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CHRS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43. The figures come from the XBRL data in the 10-K.

What did CHRS report in its latest 8-K?

Coherus Oncology, Inc. (CHRS) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest CHRS SEC filings?

Coherus Oncology, Inc. (CHRS) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 9, 2026.

What is CHRS's SEC CIK number?

Coherus Oncology, Inc. (CHRS)'s SEC Central Index Key (CIK) is 1512762. EDGAR lists every CHRS filing under that number.

Ask anything about CHRS

The research agent reads CHRS's filings, financials, insider trades and 13F holders, then answers with sources.